Peter Schmid, MD, PhD, of Queen Mary University of London, discusses phase II study findings on AZD5363 plus paclitaxel vs placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (Abstract 1007).
Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Aditya Bardia, MD, MPH, of Massachusetts General Hospital, discuss the efficacy of sacituzumab govitecan for treatment-refractory hormone receptor–positive/HER2-negative metastatic breast cancer (Abstract 1004).
Robert M. Jotte, MD, PhD, of Rocky Mountain Cancer Centers, discusses phase III study findings on atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel, as first-line therapy in advanced squamous non–small cell lung cancer (Abstract LBA9000).
Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and François Quenet, MD, of the Institut Régional du Cancer de Montpellier, discuss phase III study findings on hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis (Abstract LBA3503).
Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Susan F. Dent, MD, of The Ottawa Hospital Cancer Centre, analyze the phase III study findings on taselisib plus fulvestrant vs fulvestrant in patients with estrogen receptor–positive, PIK3CA-mutant, locally advanced or metastatic breast cancer (Abstract LBA1006).
Rita Elias Assi, MD, of The University of Texas MD Anderson Cancer Center, discusses the impact of next-generation sequencing on treatment selection in acute myeloid leukemia (Abstract 103).
